January 12, 2021 – Taiho Oncology and Servier to Present Data on LONSURF® (trifluridine and tipiracil) at 2021 ASCO Gastrointestinal Cancers Symposium
PRINCETON, N.J., January 12, 2021 – Taiho Oncology, Inc. and Servier today announced that data for LONSURF® (trifluridine and tipiracil) in previously treated patients with metastatic gastric cancer (mGC) and metastatic gastroesophageal junction adenocarcinoma (mGEJC) will be presented during the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), taking place virtually from January 15-17, 2021.
← November 1, 2020 – Taiho Oncology Joins Advocacy Organizations to Support Patients and Caregivers During Gastric Cancer Awareness MonthApril 10, 2021 – Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT™, and Zanidatamab Mechanisms of Action at AACR Annual Meeting →